El interés en corto de Prothena Corp da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Prothena Corp. Los datos de interés en corto se actualizan cada dos semanas.

Prothena Corp (NASDAQ:PRTA) Bolsa, Informe de interés en corto

Prothena Corp

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>UBS cut Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $83 to $80. UBS analyst Kevin Caliendo maintained a Neutral rating. Henry Schein shares closed at $75.82 on Tuesday. See how other <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from $94 to $110. Piper Sandler analyst Yasmeen Rahimi maintained an Overweight rating. Prothena shares closed at $14.63 on Tuesday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity increased ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $14 to $15. Canaccord Genuity analyst David Hynes maintained a Buy rating. ZoomInfo shares closed at $9.53 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut the price target for ZipRecruiter, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) from $9 to $8. Goldman Sachs analyst Eric Sheridan maintained a Neutral rating. ZipRecruiter shares closed at $6.73 on Tuesday. <a href="https://www.benzinga.com/quote/ZIP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital raised the price target for agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) from $3 to $3.5. RBC Capital analyst Sean Dodge maintained an Outperform rating. agilon health shares closed at $3.63 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/AGL/analyst-ratings">view this stock</a>.</li>
<li>Roth MKM cut Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) price target from $5 to $4.5. Roth MKM analyst Philip Shen maintained a Neutral rating. Shoals Technologies Sports shares settled at $4.2650 on Tuesday. <a href="https://www.benzinga.com/quote/SHLS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer slashed Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) price target from $65 to $60. Oppenheimer analyst Jason Helfstein maintained an Outperform rating. Maplebear Brands shares closed at $48.78 on Tuesday. <a href="https://www.benzinga.com/quote/CART/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) price target from $220 to $230. Mizuho analyst Gregg Moskowitz maintained a Neutral rating. Check Point Software shares closed at $218.63 on Tuesday.  <a href="https://www.benzinga.com/quote/CHKP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan increased the price target for Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) from $200 to $209. JP Morgan analyst Jessica Fye maintained an Overweight rating. Jazz Pharmaceuticals shares settled at $139.67 on Tuesday. <a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS increased CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) price target from $396 to $450. UBS analyst Roger Boyd maintained a Buy rating. CrowdStrike shares closed at $379.75 on Tuesday. <a href="https://www.benzinga.com/quote/CRWD/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43981181/nvidia-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Nvidia Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

News

Price Target

Markets

Analyst Ratings

Trading Ideas

CART

CHKP

CRWD

HSIC

JAZZ

SHLS

CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday

Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Overweight and raises the price target from $94 to $110.

Piper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $110

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $45.33, a high estimate of $80.00, and a low estimate of $20.00. This current average has decreased by 11.12% from the previous average price target of $51.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740402011_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Prothena Corp's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Prothena Corp's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Prothena Corp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Prothena Corp: A Closer Look</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Financial Milestones: Prothena Corp's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Prothena Corp's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 118.87%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -2729.91%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -11.35%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Prothena Corp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -10.15%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Prothena Corp Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $48 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $48 Price Target

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Sector Perform and lowers the price target from $24 to $20.

RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $20

Cantor Fitzgerald analyst Eric Schmidt reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) from Overweight to Overweight.

Cantor Fitzgerald Reiterates Overweight on Prothena Corpto Overweight

Citizens Capital Markets analyst Jason Butler reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Market Outperform and maintains $80 price target.

Citizens Capital Markets Reiterates Market Outperform on Prothena Corp, Maintains $80 Price Target

Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and maintains $40 price target.

Chardan Capital Maintains Buy on Prothena Corp, Maintains $40 Price Target

The Company expects full year 2025 net cash used in operating and investing activities to be $168 to $175 million and expects to end the year with approximately $301 million (midpoint) in cash, cash equivalents and restricted cash.&nbsp;
The estimated full year 2025 net cash used in operating and investing activities is primarily driven by an estimated net loss of $197 to $205 million, which includes an estimated $41 million of non-cash share-based compensation expense.

Guidance

Prothena Estimates FY25 Net Loss Of $(197)M - $(205)M

Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(1.04) by 3.85 percent. This is a 14.29 percent increase over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $2.12 million which missed the analyst consensus estimate of $7.53 million by 71.82 percent. This is a 571.84 percent increase over sales of $316.00 thousand the same period last year.

Earnings

Earnings Misses

Prothena Corp Q4 2024 GAAP EPS $(1.08) Misses $(1.04) Estimate, Sales $2.12M Miss $7.53M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CELH

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Prothena Corp and provided 12-month price targets. The average target is $51.2, accompanied by a high estimate of $84.00 and a low estimate of $22.00. Highlighting a 18.73% decrease, the current average has fallen from the previous average price target of $63.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1738951244_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Prothena Corp. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Prothena Corp's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Prothena Corp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Prothena Corp Better</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Key Indicators: Prothena Corp's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Prothena Corp's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -98.86%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Prothena Corp's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -6082.58%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -10.57%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Prothena Corp's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -9.51%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Prothena Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)

Shares of IMAC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) rose sharply in today's pre-market trading after the company announced it launched Ignite Proteomics, <a href="https://www.benzinga.com/quote/BACK">its new subsidiary</a>.
IMAC shares jumped 108.6% to $1.73 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Dunxin Financial Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NYSE">DXF</a>) gained 110.6% to $16.32 in pre-market trading after dipping 73% on Monday.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) rose 85.7% to $5.72 in pre-market trading following a 43% surge on Monday.</li>
<li>ZK International Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZKIN#NASDAQ">ZKIN</a>) gained 47% to $0.9998 in pre-market trading after the company reported a year-over-year increase in FY24 EPS results.</li>
<li>Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) gained 32.7% to $0.2191 in pre-market trading after falling 13% on Monday. Hepion Pharmaceuticals recently announced a $9 million public offering.</li>
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) gained 27.2% to $8.00 in pre-market trading.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) rose 26.1% to $1.11 in pre-market trading after gaining around 18% on Monday.</li>
<li>Unity Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNTY#NASDAQ">UNTY</a>) gained 23.7% to $59.99 in pre-market trading.</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) shares jumped 14.6% to $26.99 in pre-market trading. Concentra recently announced a 5.5% increase in preliminary fourth-quarter 2024 revenue.</li>
<li>Empire Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EP#NYSE">EP</a>) rose 8.2% to $6.50 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Evergreen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGR#NASDAQ">EVGR</a>) shares fell 58.3% to $5.00 in pre-market trading.</li>
<li>Greenlight Capital Re, Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) shares fell 49.1% to $7.00 in pre-market trading.</li>
<li>Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) dipped 41.1% to $6.00 in pre-market trading.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) declined 31.4% to $11.01 in pre-market trading.</li>
<li>The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) fell 27.3% to $8.10 in today's pre-market trading. The Joint Corp recently announced a year-over-year increase in patient visits.</li>
<li>Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares dipped 26% to $10.10 in pre-market trading. Varex Imaging will report unaudited financial results for the first quarter of fiscal year 2025 on Thursday, Feb. 6.</li>
<li>Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) fell 22.2% to $9.10 in pre-market trading.</li>
<li>EVI Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVI#NYSE">EVI</a>) shares tumbled 13.1% to $16.20 in pre-market trading. EVI Industries recently announced plans to acquire Haiges Machinery.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) fell 13% to $37.00 in pre-market trading.</li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) fell 9.6% to $11.81 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43230206/jim-cramer-is-worried-about-this-consumer-cyclical-stock-7-yield-something-may-be-wrong-here">Jim Cramer Is Worried About This Consumer Cyclical Stock: 7% Yield? &#8216;Something May Be Wrong Here&#8217;</a></li>
</ul>

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Wells Fargo analyst Tiago Fauth initiated coverage on MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) with an Overweight rating and announced a price target of $9. MannKind shares closed at $6.30 on Thursday. See how other analysts view this stock.</li>
<li>Citigroup analyst Peter Christiansen initiated coverage on S&amp;P Global Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Buy rating and announced a price target of $600. S&amp;P Global shares closed at $486.56 on Thursday. <a href="https://www.benzinga.com/quote/SPGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexander Hess initiated coverage on Fair Isaac Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) with a Neutral rating and announced a price target of $2150. Fair Isaac shares closed at $2,044.89 on Thursday. <a href="https://www.benzinga.com/quote/FICO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Andrew Fein initiated coverage on Avidity Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy rating and announced a price target of $72. Avidity Biosciences shares closed at $31.05 on Thursday. See how other analysts view this stock.</li>
<li>Chardan Capital analyst Rudy Li initiated coverage on Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy rating and announced a price target of $40. Prothena shares closed at $16.01 on Thursday. <a href="https://www.benzinga.com/quote/PRTA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying SPGI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-1024x589.png" alt="" class="wp-image-701945" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/20095106/image-183.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></li>
</ul>

Initiation

FICO

MNKD

SPGI

This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Throughout the last three months, 6 analysts have evaluated Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Prothena Corp, presenting an average target of $51.5, a high estimate of $84.00, and a low estimate of $22.00. This current average represents a 17.2% decrease from the previous average price target of $62.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1734699613_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Prothena Corp. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Rudy Li</td>
<td>Chardan Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$22.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Prothena Corp. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Prothena Corp compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Prothena Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Prothena Corp's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PRTA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Prothena Corp analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Prothena Corp</h2>
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
<h3>Financial Insights: Prothena Corp</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Challenges: Prothena Corp's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -98.86%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -6082.58%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Prothena Corp's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.57%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Prothena Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Prothena Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Prothena Corp: Insights From 6 Analyst Reviews

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy and lowers the price target from $84 to $48.

HC Wainwright & Co. Reiterates Buy on Prothena Corp, Lowers Price Target to $48

Chardan Capital analyst Rudy Li initiates coverage on Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Buy rating and announces Price Target of $40.

Chardan Capital Initiates Coverage On Prothena Corp with Buy Rating, Announces Price Target of $40

B of A Securities analyst Tazeen Ahmad maintains Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) with a Neutral and lowers the price target from $26 to $22.

B of A Securities Maintains Neutral on Prothena Corp, Lowers Price Target to $22

On Thursday, Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) released results from the Phase 2b PADOVA study of prasinezumab in early-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42568873/roches-phase-iib-study-of-prasinezumab-missed-primary-endpoint-but-suggests-possible-clinical-bene" rel="noreferrer noopener">stage Parkinson&#8217;s disease</a>.
Partner Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) conducted the 586-subject study investigating prasinezumab in early-stage Parkinson&#8217;s disease patients who had been treated for a minimum of 18 months while on stable symptomatic treatment.
Prasinezumab <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2024-12-19" rel="noreferrer noopener">showed</a> a potential clinical effect in the primary endpoint of time to confirmed motor progression with an HR=0.84 and p=0.0657, missing statistical significance.
The companies said the effect of prasinezumab was more pronounced in a pre-specified analysis in the population treated with levodopa (75% of participants), HR=0.79 and nominal p=0.0431.
Pre-specified supplementary covariate-adjusted analyses of these endpoints demonstrated nominally significant effects on the primary endpoint (HR=0.81; nominal p=0.0334) and in the levodopa subgroup (HR=0.76; nominal p=0.0175).
Consistent positive trends across multiple secondary and exploratory endpoints were also observed. Prasinezumab continues to be well tolerated, and no new safety signals were observed in the study.
The Phase 2 PASADENA and Phase 2b PADOVA open-label extension studies will continue to explore the observed effects in both studies.
Roche will continue to evaluate the data and work together with health authorities to determine the next steps.
Full results from the PADOVA study will be presented at an upcoming medical meeting.
Price Action: PRTA stock is up 32.40% at $15.83 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision &#8211; Here&#8217;s Why</a></li>
</ul>

Biotech

Large Cap

Health Care

Movers

General

RHHBY

Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits

Press Releases

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Announces Leadership Team Updates

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Announces Board of Directors Update

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Comments

Prothena Corp

Interés en corto

Prothena Corp (NASDAQ:PRTA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL